Document:

Royalty Termination Agmt among Biovest, LV Administrative and the Lenders

 Exhibit 10.22 
 ROYALTY TERMINATION AGREEMENT 
 THIS ROYALTY
TERMINATION AGREEMENT (this “Agreement”) is made as of November 17, 2010, by and between BIOVEST INTERNATIONAL, INC., a Delaware corporation (“Biovest”), on the one hand, and LV ADMINISTRATIVE SERVICES,
INC., a Delaware corporation, as administrative and collateral agent for the Lenders (the “Agent”), and LAURUS MASTER FUND, LTD. (IN LIQUIDATION), VALENS U.S. SPV I, LLC, VALENS OFFSHORE SPV I, LTD., VALENS OFFSHORE SPV II, CORP.
(“Valens Offshore II”) and PSOURCE STRUCTURED DEBT LIMITED (collectively, the “Prepetition Lenders” and together with the Agent, the “Creditor Parties”), on the other hand. 

RECITALS 
 WHEREAS, on October 30, 2007, Biovest and Valens Offshore II entered into a Note Purchase Agreement (the “October 2007 Purchase Agreement”), pursuant to which Valens Offshore
II purchased a Secured Promissory Note in the original principal amount of $255,000.00 from Biovest; 

WHEREAS, in connection with the October 2007 Purchase Agreement, Biovest and Valens Offshore II entered into a
Royalty Agreement dated as of October 30, 2007 (the “October 2007 Royalty Agreement”), pursuant to which Biovest granted to Valens Offshore II a royalty equal to 1.08% of net sales and licensing revenue received by Biovest from
any Biovest Biologic Products (the “October 2007 Royalty”); 
 WHEREAS, on
December 10, 2007, Biovest and Valens Offshore II entered into a Note Purchase Agreement (the “December 2007 Purchase Agreement”), pursuant to which Valens Offshore II purchased a Secured Promissory Note in the original
principal amount of $3,600,000.00 from Biovest; 
 WHEREAS, in connection with the December 2007 Purchase
Agreement, Biovest and Valens Offshore II entered into a Royalty Agreement dated as of December 10, 2007 (the “December 2007 Royalty Agreement”), pursuant to which Biovest granted to Valens Offshore II a royalty equal to 2.96%
(which, when aggregated with the October 2007 Royalty, equaled a total royalty of 4.04%) of net sales and licensing revenue received by Biovest from any Biovest Biologic Products (the “December 2007 Royalty” and together with the
October 2007 Royalty, the “Royalty”); 
 WHEREAS, on May 30, 2008, Biovest and the
Prepetition Lenders entered into a letter agreement amending the December 2007 Royalty Agreement (the “May 2008 Agreement” and together with the October 2007 Royalty Agreement and the December 2007 Royalty Agreement, the
“Royalty Agreement”), pursuant to which the December 2007 Royalty was changed from 2.96% to 9.46% (which, when aggregated with the October 2007 Royalty, equaled a total royalty of 10.54%); 

WHEREAS, pursuant to that certain Term Loan and Security Agreement (the “Security Agreement”)
dated as of November 17, 2010, by and among Biovest, the Lenders party thereto and the Agent, the parties hereto, in consideration for the acceptance by certain of the Prepetition Lenders of the allowed secured claims against Biovest as
provided therein, have agreed, among other things, to (i) the termination of the Royalty Agreement and the Royalty and (ii) the 

  
 -1-

 
granting to certain of the Lenders of a contingent payment equal to 6.25% of the gross revenue received from the sale, licensing or other disposition of the BiovaxID® vaccine and Biovest
Biologic Products, pursuant to those certain Contingent Payment Agreements of even date herewith between Biovest and certain of the Lenders; and 
 WHEREAS, pursuant to the terms and conditions of the Security Agreement and the Confirmed Plan, the parties hereto hereby desire to terminate the Royalty Agreement and the Royalty effective as of
the date of this Agreement. 
 NOW, THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 

1.        Capitalized terms used but not defined herein shall have the meanings
ascribed to them in the Security Agreement. 
 2.        The parties
hereto agree that the above Recitals are true and correct in all respects. 

3.        The parties hereto hereby consent to the termination of the Royalty
Agreement and the Royalty (and all of the rights and obligations created thereunder) effective as of the date of this Agreement. 
 4.        Each of the Creditor Parties hereby acknowledges and agrees that it shall have no claims of any nature whatsoever against Biovest as a result of the
termination of the Royalty Agreement and the Royalty. 
 5.        This
Agreement shall be binding upon the parties hereto and their respective successors and assigns. The parties hereto agree that this Agreement is fully and adequately supported by consideration, is fair and reasonable, and that they have had the
opportunity to discuss this matter with counsel of their choice. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which together shall be deemed to constitute one agreement. It is
understood and agreed that if facsimile copies of this Agreement bearing facsimile signatures are exchanged between the parties hereto, such copies shall in all respects have the same weight, force and legal effect and shall be fully as valid,
binding, and enforceable as if such signed facsimile copies were original documents bearing original signature. 

6.        THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED, INTERPRETED AND
ENFORCED ACCORDING TO, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO PRINCIPLES OF CONFLICT OF LAWS PROVISIONS THEREOF. ANY ACTION BROUGHT CONCERNING THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT SHALL BE BROUGHT ONLY IN THE STATE
COURTS OF NEW YORK OR IN THE FEDERAL COURTS LOCATED IN THE STATE OF NEW YORK. The prevailing party shall be entitled to recover from the other party its reasonable attorneys’ fees and costs. Wherever possible each provision of this
Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective to the extent of such
prohibition or invalidity, 

 
without invalidating the remainder of such provision or the remaining provisions of this Agreement. 
 [remainder of page intentionally left blank] 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as
of the date first above written. 
  

			
	BIOVEST INTERNATIONAL, INC.
		
	By:	 	 /s/ David
Moser

			
	Name:	 	  David Moser
	Title:	 	  Secretary

  

			
	LV ADMINISTRATIVE SERVICES, INC.
		
	By:	 	 /s/ Patrick
Regan

			
	Name:	 	  Patrick Regan

			
	Title:	 	Authorized Signatory

  

			
	LAURUS MASTER FUND, LTD. (IN LIQUIDATION)
		
	By:	 	 /s/ Russell
Smith

			
	Name:	 	 Russell Smith
	Title: Joint Official Liquidator (with no personal liability)

 

			
	VALENS U.S. SPV I, LLC
		
	By:	 	 /s/ Patrick
Regan

			
	Name:	 	  Patrick Regan

			
	Title:	 	Authorized Signatory

  

			
	VALENS OFFSHORE SPV I, LTD.
		
	By:	 	 /s/ Patrick
Regan

			
	Name:	 	  Patrick Regan

			
	Title:	 	Authorized Signatory

  

			
	VALENS OFFSHORE SPV II, CORP.
		
	By:	 	 /s/ Patrick
Regan

			
	Name:	 	  Patrick Regan

			
	Title:	 	Authorized Signatory

  

			
	PSOURCE STRUCTURED DEBT LIMITED
	By: PSource Capital Ltd, It’s Investment Consultant
		
	By:	 	 /s/ Charles
Lews

			
	Name:	 	Charles Lews

			
	Title:	 	Associate DirectorRoyalty Termination Agmt between Biovest and Accentia Biopharmaceuticals

 Exhibit 10.23 
 ROYALTY TERMINATION AGREEMENT 
 THIS ROYALTY
TERMINATION AGREEMENT (this “Agreement”) is made as of November 17, 2010, by and between BIOVEST INTERNATIONAL, INC., a Delaware corporation (“Biovest”), and ACCENTIA BIOPHARMACEUTICALS, INC., a Florida
corporation (“Accentia”). 
 RECITALS 

WHEREAS, pursuant to that certain Royalty Agreement dated as of October 31, 2006, as amended by a letter
agreement dated February 5, 2008 (the “Royalty Agreement”), by and between Biovest and Accentia, Biovest granted to Accentia a royalty equal to nineteen and one-half percent (19.5%) of net sales and licensing revenue
received by Biovest from any Biovest Biologic Products (the “Royalty”); 
 WHEREAS,
pursuant to that certain Term Loan and Security Agreement (the “Security Agreement”) dated as of November 17, 2010, by and among Biovest, the Lenders party thereto and Agent, the parties hereto, in consideration for the
acceptance by certain of the Prepetition Lenders of the allowed secured claims against Biovest as provided therein and other consideration, have agreed, among other things, to the termination of the Royalty Agreement and the Royalty; and 

WHEREAS, pursuant to the terms and conditions of the Security Agreement and the Confirmed Plan, Biovest and
Accentia hereby desire to terminate the Royalty Agreement and the Royalty effective as of the date of this Agreement. 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 

1.         Capitalized terms used but not defined herein shall have the meanings
ascribed to them in the Security Agreement. 
 2.         The parties
hereto agree that the above Recitals are true and correct in all respects. 
 3.
        The parties hereto hereby consent to the termination of the Royalty Agreement and the Royalty (and all of the rights and obligations created thereunder) effective as of the date of this Agreement.

 4.         Accentia hereby acknowledges and agrees that it shall have
no claims of any nature whatsoever against Biovest as a result of the termination of the Royalty Agreement and the Royalty. 
 5.         This Agreement shall be binding upon the parties hereto and their respective successors and assigns. The parties hereto agree that this Agreement is
fully and adequately supported by consideration, is fair and reasonable, and that they have had the opportunity to discuss this matter with counsel of their choice. This Agreement may be executed in one or more counterparts, each of which shall be
deemed an original and all of which together shall be deemed to constitute one agreement. It is understood and agreed that if facsimile copies of this Agreement bearing facsimile signatures are exchanged between the parties hereto, such copies

  
 -1-

 
shall in all respects have the same weight, force and legal effect and shall be fully as valid, binding, and enforceable as if such signed facsimile copies were original documents bearing
original signature. 
 6.         THIS AGREEMENT SHALL BE GOVERNED BY,
AND CONSTRUED, INTERPRETED AND ENFORCED ACCORDING TO, THE LAWS OF THE STATE OF FLORIDA, WITHOUT REGARD TO PRINCIPLES OF CONFLICT OF LAWS PROVISIONS THEREOF. ANY ACTION BROUGHT CONCERNING THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT SHALL BE
BROUGHT ONLY IN THE STATE COURTS OF FLORIDA OR IN THE FEDERAL COURTS LOCATED IN THE STATE OF FLORIDA. The prevailing party shall be entitled to recover from the other party its reasonable attorneys’ fees and costs. Wherever possible each
provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement. 
 [remainder of page intentionally left blank] 

 IN WITNESS WHEREOF, the undersigned have executed this Royalty
Termination Agreement as of the date first above written. 
  

			
	BIOVEST INTERNATIONAL, INC.
		
	By:	 	 /s/ David Moser

	Name:	 	David Moser
	Title:	 	Secretary
	
	ACCENTIA BIOPHARMACEUTICALS, INC.
		
	By:	 	 /s/ Samuel S. Duffey

	Name:	 	Samuel S. Duffey
	Title:	 	President

  

			
	ACCEPTED AND AGREED:
	
	LV ADMINISTRATIVE SERVICES, INC.
		
	By:	 	 /s/ Patrick Regan

	Name: Patrick Regan
	Title: Authorized Signatory
	
	LAURUS MASTER FUND, LTD. (IN LIQUIDATION)
		
	By:	 	 /s/ Russell Smith

	Name: Russell Smith
	Title: Joint Official Liquidator (with no personal liability)
	
	VALENS U.S. SPV I, LLC
		
	By:	 	 /s/ Patrick Regan

	Name: Patrick Regan
	Title: Authorized Signatory
	
	VALENS OFFSHORE SPV I, LTD.
		
	By:	 	 /s/ Patrick Regan

	Name: Patrick Regan
	Title: Authorized Signatory
	
	VALENS OFFSHORE SPV II, CORP.
		
	By:	 	 /s/ Patrick Regan

	Name: Patrick Regan
	Title: Authorized Signatory
	
	PSOURCE STRUCTURED DEBT LIMITED

 
			
	By: PSource Capital Ltd., It’s Investment Consultant
		
	 By:
	 	 /s/ Charles Lews

	 Name: Charles Lews

	 Title: Authorized Signatory

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}]]